Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Autor principal: | Hoque, Ismoth Ara |
---|---|
Altres autors: | Azam, Faruque |
Format: | Thesis |
Idioma: | English |
Publicat: |
Brac University
2024
|
Matèries: | |
Accés en línia: | http://hdl.handle.net/10361/23164 |
Ítems similars
-
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
per: Paul, Pulock
Publicat: (2024) -
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
per: Rahman, Tasnim
Publicat: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
per: Karim, Samia Binte
Publicat: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
per: Flora, Sanzida Alam
Publicat: (2024) -
Molecules associated with the development of lung cancer
per: Rahman, Adree, et al.
Publicat: (2023)